- Home
- STTK vs PESI Comparison
STTK vs PESI Comparison
Compare STTK & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PESI
- Stock Information
- Founded
- STTK 2016
- PESI 1990
- Country
- STTK United States
- PESI United States
- Employees
- STTK N/A
- PESI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PESI Environmental Services
- Sector
- STTK Health Care
- PESI Industrials
- Exchange
- STTK Nasdaq
- PESI Nasdaq
- Market Cap
- STTK 83.8M
- PESI 205.4M
- IPO Year
- STTK 2020
- PESI 1992
- Fundamental
- Price
- STTK $1.94
- PESI $8.19
- Analyst Decision
- STTK Hold
- PESI
- Analyst Count
- STTK 6
- PESI 0
- Target Price
- STTK $2.67
- PESI N/A
- AVG Volume (30 Days)
- STTK 1.6M
- PESI 283.8K
- Earning Date
- STTK 11-13-2025
- PESI 11-12-2025
- Dividend Yield
- STTK N/A
- PESI N/A
- EPS Growth
- STTK N/A
- PESI N/A
- EPS
- STTK N/A
- PESI N/A
- Revenue
- STTK $2,997,000.00
- PESI $60,019,000.00
- Revenue This Year
- STTK N/A
- PESI $8.35
- Revenue Next Year
- STTK N/A
- PESI $82.81
- P/E Ratio
- STTK N/A
- PESI N/A
- Revenue Growth
- STTK N/A
- PESI N/A
- 52 Week Low
- STTK $0.69
- PESI $6.25
- 52 Week High
- STTK $3.95
- PESI $16.25
- Technical
- Relative Strength Index (RSI)
- STTK 64.83
- PESI 29.05
- Support Level
- STTK $1.68
- PESI $8.02
- Resistance Level
- STTK $2.01
- PESI $12.32
- Average True Range (ATR)
- STTK 0.23
- PESI 0.82
- MACD
- STTK 0.05
- PESI -0.39
- Stochastic Oscillator
- STTK 80.82
- PESI 3.95
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.